HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study

Murrell, Derek; Cluck, David; Moorman, Jonathan P.; Brown, Stacy D.; Wang, Kesheng; Duffourc, Michelle M.; Harirforoosh, Sam

doi:10.1007/s40261-018-0739-9

Cited by 3 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 While 76% of patients in our study were taking integrase inhibitors, that have a relatively low gastrointestinal side effect profile, other medications may result in gastrointestinal symptoms. 53,54 Psychological Symptom Cluster A psychological symptom cluster was identified in previous studies that used the HIV Symptom Index. 4,21 Of note, the four symptoms identified in our study (i. e., felt sad, down, or depressed; felt nervous or anxious; fatigue or loss of energy; and difficulty falling or staying asleep were among the most common and distressing) were found in the psychological symptom cluster identified in the two previous studies.…”

Section: Gastrointestinal Symptom Clustermentioning

confidence: 99%

HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress

Wilson

Hoffman

Heath

et al. 2022

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Section: Gastrointestinal Symptom Clustermentioning

confidence: 99%

HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress

Wilson

Hoffman

Heath

et al. 2022

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Update on Adverse Effects of HIV Integrase Inhibitors

Kołakowska

Maresca

Collins

et al. 2019

Curr Treat Options Infect Dis

View full text Add to dashboard Cite

Keywords HIV integrase inhibitors I Drug-related side effects and adverse reactions I Raltegravir I Elvitegravir I Dolutegravir Abstract Purpose of review The goal of this paper is to provide an up-to-date review of adverse events related to the class of integrase strand transfer inhibitors (INSTIs), which became the class of choice in few years. We sought answers specifically to issues pertaining to neuropsychiatric adverse events, as well as weight gain, which were the two most important categories of adverse events raised in recent studies based on real-life experience. The primary focus of this paper is on adults with a brief summary on pregnant women and children/adolescents. Recent findings Dolutegravir (DTG) bears the heaviest burden of neuropsychiatric side effects. Weight gain was reported with all INSTIs, although there are methodological caveats in the analyses and the findings need to be interpreted with caution. Moreover, due to recent findings on neural tube defects in infants exposed to dolutegravir during their peri-conception period, its use is not recommended for women of childbearing age without proper birth control method, while raltegravir remains the only drug which may be prescribed without caution. Given the importance of cognitive and metabolic comorbidities in people living with HIV in regard to their quality of life, future research needs to focus on long-term effects of INSTIs in relation to these adverse events. Pharmacogenetics seems to be a promising tool. Safety during pregnancy is also another important issue to further clarify. Summary INSTIs are a generally well-tolerated class of antiretrovirals (ARV), and has a

show abstract

Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers

Fankhouser

Murrell

Anane

et al. 2022

Drug Metabolism and Personalized Therapy

View full text Add to dashboard Cite

Objectives This study sought to identify potential pharmacogenetic associations of selected enzymes and transporters with type 2 diabetes (T2D). In addition, pharmacogenomic profiles, concentrations of asymmetric dimethylarginine (ADMA) or kidney injury molecule-1 (KIM-1), and several covariates were investigated. Methods Whole blood was collected from 63 patients, with 32 individuals with T2D. A pharmacogenomic panel was used to assay genetic profiles, and biomarker ELISAs were run to determine subject concentrations of ADMA and KIM-1. Additive genetic modeling with multiple linear and logistic regressions were performed to discover potential SNPs-outcome associations using PLINK. Results Ten SNPs were found to be significant (p<0.05) depending on the inclusion or exclusion of covariates. Of these, four were found in association with the presence of T2D, rs2231142, rs1801280, rs1799929, and rs1801265 depending on covariate inclusion or exclusion. Regarding ADMA, one SNP was found to be significant without covariates, rs1048943. Five SNPs were identified in association with KIM-1 and T2D in the presence of covariates, rs12208357, rs34059508, rs1058930, rs1902023, and rs3745274. Biomarker concentrations were not significantly different in the presence of T2D. Conclusions This exploratory study found several SNPs related to T2D; further research is required to validate and understand these relationships.

show abstract

HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study

Cited by 3 publications

References 50 publications

HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress

HIV Symptom Clusters are Similar Using the Dimensions of Symptom Occurrence and Distress

Update on Adverse Effects of HIV Integrase Inhibitors

Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers

Contact Info

Product

Resources

About